Syneos Health · 1 day ago
Senior Regulatory Consultant (NA and LATAM Only)
Syneos Health is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. The Senior Regulatory Consultant will be responsible for the development of regulatory submissions and post marketing regulatory support for clients, including regulatory writing and ensuring compliance with relevant guidelines and standards.
BiotechnologyHealth CarePharmaceuticalTherapeutics
Responsibilities
Responsible for the development of regulatory submissions and post marketing regulatory support for clients
This includes authorship of portions of regulatory submissions, regulatory writing, regulatory research, and ensuring compliance with relevant guidelines and standards
Responsible for providing advice and assistance to clients and other associates in areas of expertise and may manage smaller client projects
Supports new business development in area of expertise
Qualification
Required
Must be located in NA or LATAM with no sponsorship needs
Please submit all resumes in English
Responsible for the development of regulatory submissions and post marketing regulatory support for clients
This includes authorship of portions of regulatory submissions, regulatory writing, regulatory research, and ensuring compliance with relevant guidelines and standards
Responsible for providing advice and assistance to clients and other associates in areas of expertise and may manage smaller client projects
Supports new business development in area of expertise
Benefits
Company car or car allowance
Health benefits to include Medical, Dental and Vision
Company match 401k
Eligibility to participate in Employee Stock Purchase Plan
Eligibility to earn commissions/bonus based on company and individual performance
Flexible paid time off (PTO) and sick time
Company
Syneos Health
Syneos Health, the only fully integrated end-to-end clinical and commercial solution organization.
Funding
Current Stage
Public CompanyTotal Funding
$524.65M2023-09-28Private Equity
2023-05-10Acquired
2021-03-01Post Ipo Secondary· $524.65M
Leadership Team
Recent News
2025-12-01
Company data provided by crunchbase